Stroke drug given during ambulance ride could boost recovery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 80 years (inclusive). * Time from last known normal to arrival at the first hospital is within 6 hours. * Clinical and imaging diagnosis of acute ischemic stroke, with a Los Angeles Motor Scale (LAMS) score ≥ 4, or occlusion of the internal carotid artery, M1/M2 segment of the middle cerebral artery, V4 segment of the vertebral artery, or basilar artery confirmed by CTA/MRA at the first or target hospital. * ASPECTS score ≥ 6 on non-contrast head CT at the first hospital. * Clinically assessed as planned for immediate transfer to a target hospital for evaluation of endovascular therapy (final decision on whether to perform EVT is made by the neuro-interventionist at the target hospital based on imaging and clinical status). * Written informed consent signed by the patient or their legal representative. Exclusion Criteria: * Allergy to contrast agents, nickel, titanium, or their alloys. * Known allergy to dexborneol, edaravone, or excipients. * Pre-stroke modified Rankin Scale (mRS) score ≥ 2. * Patients receiving intravenous thrombolysis alone. * Severe impairment of consciousness (e.g., GCS score \< 8) or inability to cooperate with sublingual administration. * Severe hepatic or renal insufficiency (e.g., ALT/AST \> 3 times the upper limit of normal, Cr \> 2 times the upper limit of normal). * Estimated inter-hospital transfer time \> 3 hours. * Pregnant or lactating women. * Arterial tortuosity and/or other arterial diseases where the thrombectomy device is expected to be unable to reach the target vessel. * Brain tumors with mass effect on imaging (except small meningiomas). * Currently participating in other drug clinical trials. * History of neurological or psychiatric diseases that hinder the assessment of neurological function. * Any late-stage disease with an expected life expectancy \< 6 months.